The success of copyright’s blockbuster initially fueled a surge for pharma, but recent shifts present a murky outlook for investors. Off-patent alternatives are eating into earnings, and continued legal battles add more difficulty to the equation. While certain companies might still see gains from adjacent offerings, the general trend suggests a